Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 209.00
Bid: 208.00
Ask: 215.00
Change: -6.00 (-2.79%)
Spread: 7.00 (3.365%)
Open: 212.00
High: 214.00
Low: 207.00
Prev. Close: 215.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

10 Mar 2020 07:00

RNS Number : 5158F
PureTech Health PLC
10 March 2020
 

10 March 2020

PureTech Health plc

 

Notice of Results

 

PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company") plans to announce its financial results for the year ended 31 December 2019 on Thursday, 9 April 2020.

 

A presentation and conference call for analysts will take place at 2:00pm BST / 9:00am EDT, and a webcast of the presentation will be available on the Company's website at http://puretechhealth.com/investors under the Reports and Presentations tab.

 

PureTech also confirms that the global outbreak of COVID-19 has not adversely affected the Company's business of addressing major diseases through its leadership in immunology and the Brain-Immune-Gut (BIG) Axis. The Company has a very strong cash position and is advancing the business in accordance with its previously announced strategy and timelines while continuing to monitor the situation.

 

About PureTech Health

PureTech is a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's affiliates, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBCGDXUXGDGGC
Date   Source Headline
10th May 20165:49 pmRNSResult of AGM
10th May 20167:00 amRNSFirst Capital Markets Meeting
10th May 20167:00 amRNSLaunch of Alivio Therapeutics
9th May 20167:00 amRNSLaunch of Vor BioPharma
6th May 20167:00 amRNSAkili Opens Enrolment for Pivotal Trial
5th May 20167:00 amRNSThe Sync Project Teams with World-Renowned Artists
3rd May 20167:00 amRNSGelesis200 Positive Safety Results
3rd May 20167:00 amRNSDirector Dealing
26th Apr 20169:00 amRNSFirst US Patient Enrolled in Gelesis100 Study
7th Apr 20167:33 amRNSFinal Results
31st Mar 20169:00 amRNSExpands Microbiome Focus with "Commense"
30th Mar 20169:00 amRNSVedanta Biosciences Announces Licence with RIKEN
16th Mar 20169:00 amRNSVedanta Appoints New Chief Scientific Officer
23rd Feb 20169:00 amRNSPresenting at Cowen and Company Conference
16th Feb 20169:00 amRNSNotice of Results
27th Jan 20169:00 amRNSExpands SAB and appoints new Senior Advisors
22nd Jan 20167:00 amRNSOperating Company Akili Raises $30.5 Million
19th Jan 20167:00 amRNSFirst Capital Markets Meeting
18th Dec 20157:00 amRNSGelesis Closes $31.5m Growth Financing
30th Nov 20157:00 amRNSNames Scientific Advisory Board and Expands Team
5th Nov 20157:00 amRNSThe Sync Project
2nd Nov 20157:00 amRNSTo Present at Jefferies 2015 Conference
28th Oct 20155:02 pmRNSAkili Study - Improved Attention & Memory in ADHD
26th Oct 20157:00 amRNSDirector Dealing
9th Oct 201512:03 pmRNSDirector Dealing
5th Oct 20157:00 amRNSAnnouncement Regarding Listing Rule 6.1.19R
1st Oct 20157:00 amRNSDirector/PDMR Shareholding
28th Sep 20157:00 amRNSDirector Dealing
24th Sep 201512:14 pmRNSHolding(s) in Company
16th Sep 20157:00 amRNSDirector Dealing
14th Sep 20157:00 amRNSAppoints Michael MacLean as CFO
10th Sep 20159:30 amRNSDirector Dealing
9th Sep 20159:17 amRNSDirector Dealing
4th Sep 20154:00 pmRNSFollica Receives Notification of Patent Allowance
4th Sep 20158:15 amRNSDirector Dealing
3rd Sep 20157:00 amRNSDirector Dealing
25th Aug 20157:00 amRNSHalf Yearly Report
19th Aug 201512:00 pmRNSNotice of Half-Yearly Results
5th Aug 20157:00 amRNSKaruna Receives Wellcome Trust Award
27th Jul 20157:00 amRNSGelesis Expands Ongoing Weight Loss Study
21st Jul 20153:40 pmRNSHolding(s) in Company
17th Jul 201512:26 pmRNSDirector/PDMR Shareholding
7th Jul 20153:30 pmRNSHolding(s) in Company
3rd Jul 20153:39 pmRNSExercise of overallotment option - Admission
3rd Jul 20157:01 amRNSExercise of Over-allotment Option
3rd Jul 20157:00 amRNSEnd of Stabilisation Notice
26th Jun 20153:18 pmRNSHolding(s) in Company
24th Jun 20154:25 pmRNSHolding(s) in Company
24th Jun 20158:00 amRNSAdmission to Trading on the London Stock Exchange
19th Jun 20152:17 pmRNSPublication of Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.